Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + simvastatin Laboratorio Farmaceutico C.T.
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ezetimibe + simvastatin Laboratorio Farmaceutico C.T. is a small molecule combination drug developed by the Italian pharmaceutical company Laboratorio Farmaceutico C.T. for the management of dyslipidemia and hypercholesterolemia. The product combines two lipid-lowering agents with complementary mechanisms of action: ezetimibe and simvastatin. Ezetimibe selectively inhibits the intestinal absorption of cholesterol and related phytosterols by targeting the Niemann-Pick C1-Like 1 (NPC1L1) transport protein. Simvastatin is an HMG-CoA reductase inhibitor (statin) that suppresses the endogenous synthesis of cholesterol in the liver. By addressing both the absorption and production of cholesterol, the combination effectively reduces levels of low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides while increasing high-density lipoprotein (HDL) cholesterol. This product is an approved generic version of the branded medications Vytorin and Inegy.
- Other names
- ezetimibe/simvastatin CT
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on ezetimibe + simvastatin Laboratorio Farmaceutico C.T..
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + simvastatin Laboratorio Farmaceutico C.T..